SMLR · As filed with the SEC
Semler Scientific cash flow statement, by quarter
The statement as Semler Scientific presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
Condensed Consolidated Statements of Cash Flows · USD
| USD | Q3 2025 3 months ended Sep 30, 2025 | Q2 2025 3 months ended Jun 30, 2025 | Q1 2025 3 months ended Mar 31, 2025 | Q4 2024 3 months ended Dec 31, 2024 |
|---|---|---|---|---|
| CASH FLOWS FROM OPERATING ACTIVITIES: | ||||
| Net income | — | — | (64,702,000) | — |
| Reconciliation of Net Income to Net Cash (Used in) Provided by Operating Activities: | ||||
| Depreciation | — | — | 120,000 | — |
| Amortization of debt issuance costs | — | — | 111,000 | — |
| Deferred tax expense (benefit) | — | — | (10,284,000) | — |
| Loss on disposal of assets for lease | — | — | 105,000 | — |
| Allowance for credit losses | — | — | (52,000) | — |
| Change in fair value of digital assets | — | — | 41,829,000 | — |
| Stock-based compensation | — | — | 1,483,000 | — |
| Impairment of investments | — | — | 1,135,000 | — |
| Changes in Operating Assets and Liabilities: | ||||
| Trade accounts receivable | — | — | 1,306,000 | — |
| Inventory | — | — | (12,000) | — |
| Prepaid expenses and other current assets | — | — | (2,188,000) | — |
| Other non-current assets | — | — | 21,000 | — |
| Accounts payable | — | — | 451,000 | — |
| Accrued interest | — | — | 616,000 | — |
| Accrued expenses | — | — | 28,241,000 | — |
| Other current and non-current liabilities | — | — | (23,000) | — |
| Deferred revenue | — | — | (63,000) | — |
| Net Cash (Used in) Provided by Operating Activities | — | — | (1,906,000) | — |
| CASH FLOWS FROM INVESTING ACTIVITIES: | ||||
| Purchase of digital assets | — | — | (90,700,000) | — |
| Proceeds from maturities of notes receivable | — | — | 3,600,000 | — |
| Purchase of assets for lease | — | — | (210,000) | — |
| Net Cash Used in Investing Activities | — | — | (87,310,000) | — |
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||||
| Proceeds from issuance of debt | — | — | 100,000,000 | — |
| Debt issuance costs | — | — | (4,017,000) | — |
| Capital call premium | — | — | (7,740,000) | — |
| Proceeds from issuance of common stock | — | — | 2,187,000 | — |
| Stock issuance expenses | — | — | (295,000) | — |
| Net Cash Provided by Financing Activities | — | — | 90,135,000 | — |
| NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS | — | — | 919,000 | — |
| CASH, CASH EQUIVALENTS AND RESTRICTED CASH, BEGINNING OF PERIOD | 13,616,000 | 9,871,000 | 8,952,000 | 6,701,000 |
| CASH, CASH EQUIVALENTS AND RESTRICTED CASH, END OF PERIOD | 10,311,000 | 13,616,000 | 9,871,000 | 8,952,000 |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.